{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-025558","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.720029+00:00","generated_at":"2026-05-24T11:39:40.036517+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunome reports FY 2024 net loss of $293M; cash runway into 2027, pipeline milestones ahead","bullets":["Net loss $293.0M for FY 2024; cash & equivalents $217.3M at Dec 31, 2024.","January 2025 upsized offering raised $172.5M gross; cash runway now extends into 2027.","Phase 3 RINGSIDE topline data for varegacestat in desmoid tumors expected H2 2025.","Phase 1 of IM-1021 (ROR1 ADC) dosed first patient Feb 2025; IND for IM-3050 (FAP radioligand) submitted March 2025.","Preclinical ADCs IM-1617, IM-1340, IM-1335 in IND-enabling work; additional discovery programs ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-025558","json":"https://secwatch.observer/filing/0001104659-25-025558.json","markdown":"https://secwatch.observer/filing/0001104659-25-025558.md","text":"https://secwatch.observer/filing/0001104659-25-025558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465925025558/0001104659-25-025558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465925025558/tm259725d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T11:39:40.036517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}